Assessment of Galectin-1, Galectin-3, and Prostaglandin E2 Levels in Patients with COVID-19
It is important to determine the inflammatory biomarkers in the severity of coronavirus disease 2019 (COVID-19) with the emergence of the pandemic. Galectins and prostaglandins play important roles in the regulation of immune and inflammatory responses. Therefore, this study aimed to investigate Galectin-1 (Gal-1), Galectin-3 (Gal-3), and prostaglandin E2 (PGE2) levels in patients with COVID-19. Serum concentrations of Gal-1, Gal-3, and PGE2 were measured using enzyme-linked immunosorbent assay on 84 patients with COVID-19 (severe = 29 and nonsevere = 55) and 56 healthy controls. In this study, increased levels of Gal-1 (median, 9.86, 6.35, and 3.67 ng/mL), Gal-3 (median, 415.31, 326.33, and 243.13 pg/mL), and PGE2 (median, 193.17, 192.58, and 124.62 pg/mL) levels were found in patients with COVID-19 than in healthy controls (P < 0.001 for all). In the severe disease group, Gal-3 levels were higher, while no differences were noted in Gal-1 and PGE2 levels (P = 0.011, P = 0.263, and P = 0.921, respectively). Serum levels of Gal-1 were positively correlated with those of Gal-3 (P = 0.871 and P < 0.001). Gal-3, C-reactive protein, lymphocyte count, and age were found as independent predictors of disease severity (P = 0.002, P = 0.001, P = 0.007, and P = 0.003, respectively). With the emergence of effective drug needs in the COVID-19 pandemic, differentiation of severe disease is important. Therefore, Gal-3 could be a potential prognostic biomarker of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
Japanese journal of infectious diseases - 74(2021), 6 vom: 22. Nov., Seite 530-536 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kazancioglu, Sumeyye [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 15.12.2021 Date Revised 15.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7883/yoken.JJID.2021.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323457541 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323457541 | ||
| 003 | DE-627 | ||
| 005 | 20231225184227.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7883/yoken.JJID.2021.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1078.xml |
| 035 | |a (DE-627)NLM323457541 | ||
| 035 | |a (NLM)33790073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kazancioglu, Sumeyye |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of Galectin-1, Galectin-3, and Prostaglandin E2 Levels in Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2021 | ||
| 500 | |a Date Revised 15.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a It is important to determine the inflammatory biomarkers in the severity of coronavirus disease 2019 (COVID-19) with the emergence of the pandemic. Galectins and prostaglandins play important roles in the regulation of immune and inflammatory responses. Therefore, this study aimed to investigate Galectin-1 (Gal-1), Galectin-3 (Gal-3), and prostaglandin E2 (PGE2) levels in patients with COVID-19. Serum concentrations of Gal-1, Gal-3, and PGE2 were measured using enzyme-linked immunosorbent assay on 84 patients with COVID-19 (severe = 29 and nonsevere = 55) and 56 healthy controls. In this study, increased levels of Gal-1 (median, 9.86, 6.35, and 3.67 ng/mL), Gal-3 (median, 415.31, 326.33, and 243.13 pg/mL), and PGE2 (median, 193.17, 192.58, and 124.62 pg/mL) levels were found in patients with COVID-19 than in healthy controls (P < 0.001 for all). In the severe disease group, Gal-3 levels were higher, while no differences were noted in Gal-1 and PGE2 levels (P = 0.011, P = 0.263, and P = 0.921, respectively). Serum levels of Gal-1 were positively correlated with those of Gal-3 (P = 0.871 and P < 0.001). Gal-3, C-reactive protein, lymphocyte count, and age were found as independent predictors of disease severity (P = 0.002, P = 0.001, P = 0.007, and P = 0.003, respectively). With the emergence of effective drug needs in the COVID-19 pandemic, differentiation of severe disease is important. Therefore, Gal-3 could be a potential prognostic biomarker of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a PGE2 | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a galectin-1 | |
| 650 | 4 | |a galectin-3 | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Galectin 1 |2 NLM | |
| 650 | 7 | |a Galectin 3 |2 NLM | |
| 650 | 7 | |a Dinoprostone |2 NLM | |
| 650 | 7 | |a K7Q1JQR04M |2 NLM | |
| 700 | 1 | |a Yilmaz, Fatma Meric |e verfasserin |4 aut | |
| 700 | 1 | |a Bastug, Aliye |e verfasserin |4 aut | |
| 700 | 1 | |a Ozbay, Bahadir Orkun |e verfasserin |4 aut | |
| 700 | 1 | |a Aydos, Omer |e verfasserin |4 aut | |
| 700 | 1 | |a Yücel, Çiğdem |e verfasserin |4 aut | |
| 700 | 1 | |a Bodur, Hurrem |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Gulsen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Japanese journal of infectious diseases |d 1999 |g 74(2021), 6 vom: 22. Nov., Seite 530-536 |w (DE-627)NLM104387572 |x 1884-2836 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2021 |g number:6 |g day:22 |g month:11 |g pages:530-536 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7883/yoken.JJID.2021.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2021 |e 6 |b 22 |c 11 |h 530-536 | ||